Back

Empagliflozin alleviates diabetic cardiomyopathy via inhibiting excessive autophagy and adverse remodeling in type 1 diabetic mice

26 August 2022 (08:00 - 19:30)
Organised by:
Congress Presentation Part of: Cellular effectiveness of drug therapies Cardiomyopathies ESC Professional Premium Access ESC Congress 2022

About the speaker

Photo
Associate Professor Rosalinda Madonna

University of Pisa, Pisa (Italy)

5 More presentations in this session

Presentation thumbnail
Effect of sacubitril/valsartan and empagliflozin on systemic inflammation and scar remodeling in a swine model of myocardial infarction
Miss D. Martinez-Falguera (Badalona, ES)
Abstract Slides
Presentation thumbnail
The cardioprotective effect of inhibiting SGLT1 in hyperglycemia ischemia reperfusion injury
Miss A. Almalki (London, GB)
Abstract Slides
Presentation thumbnail
Upregulation of SGLT1 and 2 promotes oxidative stress in right atrial appendages of patients with low-grade inflammatory responses: potential role in atrial fibrillation
Miss W. Fakih (Strasbourg, FR)
Abstract Slides
Presentation thumbnail
SGLT1/2 expression in the heart of transplanted patients is associated with inflammatory induction of oxidative stress: Potential protective effect of SGLT2 inhibitors
Mr A. Mroueh (Strasbourg, FR)
Abstract Slides
Presentation thumbnail
Evaluation of the direct protective effects of Canagliflozin on the Isoproterenol-induced cell injury in rat cardiomyocytes.
Doctor Y. Murayama (Sagamihara, JP)
Abstract Slides

Access the full session

Session thumbnail
Cellular effectiveness of drug therapies

The Event

Event poster

ESC Congress 2022

26 August - 29 August 2022
You may be interested in
thumbnail
Congress Session
When time is the issue
thumbnail
Congress Session
Genetics in heart failure
thumbnail
Congress Session
When external causes are the villain?

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources